Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma
- PMID: 19967725
- DOI: 10.1002/path.2659
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma
Abstract
The histopathological diagnosis of high-grade endometrioid and serous carcinoma of the ovary is poorly reproducible under the current morphology based classification system, especially for anaplastic, high-grade tumours. The transcription factor Wilms' tumour-1 (WT1) is differentially expressed among the gynaecological epithelia from which epithelial ovarian cancers (EOCs) are believed to originate. In EOCs, WT1 protein is observed in the majority of serous carcinomas and in up to 30% of endometrioid carcinomas. It is unclear whether the latter is a reflection of the actual incidence of WT1 protein expression in endometrioid carcinomas, or whether a significant number of high-grade serous carcinomas have been misclassified as endometrioid carcinoma. Several genetic aberrations are reported to occur in EOCs. These include mutation of the TP53 gene, aberrant activation of beta-catenin signalling and loss of PTEN protein expression, among others. It is unclear whether these aberrations are histotype-specific. The aim of this study was to better define the molecular characteristics of serous and endometrioid carcinomas in an attempt to address the problems with the current histopathological classification methods. Gene expression profiles were analysed to identify reproducible gene expression phenotypes for endometrioid and serous carcinomas. Tissue microarrays (TMA) were used to assess the incidence of TP53, beta-catenin and PTEN aberrations in order to correlate their occurrence with WT1 as an immunohistochemistry based biomarker of serous histotype. It was found that nuclear WT1 protein expression can identify misclassified high-grade endometrioid carcinomas and these tumours should be reassigned to serous histotype. Although low-grade endometrioid carcinomas rarely progress to high-grade carcinomas, a combined WT1-negative, TP53-positive immunophenotype may identify an uncommon high-grade subtype of ovarian endometrioid carcinoma. GEO database: array data accession number GSE6008.
Copyright 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Comment in
-
Re: Madore et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010;220:392-400.J Pathol. 2010 Sep;222(1):117; author reply 118. doi: 10.1002/path.2741. J Pathol. 2010. PMID: 20572050 No abstract available.
Similar articles
-
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Pathology. 2011. PMID: 21716157 Review.
-
Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.Int J Gynecol Pathol. 2004 Apr;23(2):119-22. doi: 10.1097/00004347-200404000-00005. Int J Gynecol Pathol. 2004. PMID: 15084839
-
High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.Am J Surg Pathol. 2018 Apr;42(4):534-544. doi: 10.1097/PAS.0000000000001016. Am J Surg Pathol. 2018. PMID: 29309296
-
Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.Clin Cancer Res. 2019 Jul 15;25(14):4309-4319. doi: 10.1158/1078-0432.CCR-18-3818. Epub 2019 Apr 12. Clin Cancer Res. 2019. PMID: 30979743
-
My approach to and thoughts on the typing of ovarian carcinomas.J Clin Pathol. 2008 Feb;61(2):152-63. doi: 10.1136/jcp.2007.049478. Epub 2007 Aug 17. J Clin Pathol. 2008. PMID: 17704261 Review.
Cited by
-
Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.Br J Cancer. 2024 Nov;131(8):1340-1349. doi: 10.1038/s41416-024-02837-x. Epub 2024 Aug 30. Br J Cancer. 2024. PMID: 39215190
-
A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas.In Vivo. 2018 May-Jun;32(3):597-602. doi: 10.21873/invivo.11281. In Vivo. 2018. PMID: 29695566 Free PMC article.
-
Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification.NPJ Precis Oncol. 2021 Jun 2;5(1):47. doi: 10.1038/s41698-021-00187-y. NPJ Precis Oncol. 2021. PMID: 34079052 Free PMC article.
-
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11. J Clin Oncol. 2017. PMID: 28398847 Free PMC article.
-
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier.Genome Biol. 2014 Dec 17;15(12):526. doi: 10.1186/s13059-014-0526-8. Genome Biol. 2014. PMID: 25608477 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous